The Health Ministry said the active caseload comprised 1.21% of all Covid cases. In absolute numbers, this figure is still higher than the lowest active caseload after the first wave.
Many US colleges and universities have informed the students to get vaccinated ahead of the Autumn semester. But the students who have been inoculated with India's Covaxin or Russia's Sputnik-V were asked to get themselves re-vaccinated saying that those are not approved by the World Health Organization (WHO). "Milloni Doshi, a 25-year-old student from India, who is due to
Read more about Covid vaccine: India may grant indemnity to Pfizer, Moderna, says report on Business Standard. Countries like the US have granted these vaccine makers immunity where they cannot be sued for any adverse effects.
India’s Covid crisis is a warning for other low- and middle-income countries: IMF
PTI
Washington |
Updated on
×
‘The ongoing catastrophic second wave in India is a sign the worst may be yet to come in the developing world.’
Observing that the ongoing “catastrophic” second wave of Covid-19 in India is a sign that the worst may be yet to come, the IMF has said. The organisation also said that the situation in India is a warning of the possible events in low- and middle-income nations that have seemingly escaped the pandemic till now.
A report co-authored by International Monetary Fund (IMF) economist Ruchir Agarwal and its Chief Economist Gita Gopinath on Friday said that under the ‘business-as-usual’ scenario, the vaccine coverage in India is expected to remain under 35 per cent of the population by the end of 2021.
Discussions on with Indian government for expedited approval of COVID-19 vaccine: Pfizer
Pfizer had earlier said that it had offered a not-for-profit price for its vaccine for the immunisation programme in India and it remains committed to continuing engagement with the government.
Share Via Email
| A+A A- By PTI
NEW DELHI: Pfizer is in discussions with the Indian government for an expedited approval pathway to make Pfizer-BioNTech vaccine available in the country, its chief Albert Bourla said on Monday, while stating that the firm is donating medicines worth USD 70 million (over Rs 510 crore) for treatment of COVID-19 patients in India.